Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | STK4 | Q13043 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544253 | 0.86 | PLK2 (0.35) | PLK2PLK1SMN1; SMN2 | |
| SCHEMBL1559398 | 0.85 | PLK2 (0.35) | PLK2PLK1SMN1; SMN2 | |
| SCHEMBL30135744 | 0.85 | PLK2 (0.35) | PLK2PLK1SMN1; SMN2 | |
| SCHEMBL25035084 | 0.84 | — | — | |
| SCHEMBL3545143 | 0.83 | PLK2 (0.32) | PLK2PLK1SMN1; SMN2 | |
| SCHEMBL2342271 | 0.78 | PLK2 (0.49) | PLK2PLK1SMN1; SMN2STK4 | |
| SCHEMBL2544712 | 0.78 | PLK1 (0.38) | PLK2PLK1 | |
| SCHEMBL2874984 | 0.78 | RPS6KA3 (0.36) | SMN1; SMN2STK4 | |
| SCHEMBL1202616 | 0.77 | PLK1 (0.41) | PLK1STK4 | |
| SCHEMBL3542491 | 0.76 | PLK1 (0.40) | PLK1STK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | PLK2 1286/4885PLK1 847/4885SMN1; SMN2 1059/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | PLK2 10/4885PLK1 1/4885SMN1; SMN2 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.